RU2018103196A - Композиции и способы лечения сердечной недостаточности - Google Patents

Композиции и способы лечения сердечной недостаточности Download PDF

Info

Publication number
RU2018103196A
RU2018103196A RU2018103196A RU2018103196A RU2018103196A RU 2018103196 A RU2018103196 A RU 2018103196A RU 2018103196 A RU2018103196 A RU 2018103196A RU 2018103196 A RU2018103196 A RU 2018103196A RU 2018103196 A RU2018103196 A RU 2018103196A
Authority
RU
Russia
Prior art keywords
neuregulin
heart failure
use according
patient
cardiac function
Prior art date
Application number
RU2018103196A
Other languages
English (en)
Inventor
Миндун ЧЖОУ
Original Assignee
Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи, Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи, Ко., Лтд. filed Critical Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи, Ко., Лтд.
Publication of RU2018103196A publication Critical patent/RU2018103196A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A61K36/804—Rehmannia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)

Claims (30)

1. Применение нейрегулина для получения лекарственного средства для лечения пациента с хронической сердечной недостаточностью, где у пациента есть сердечная функция класса II или класса III, классифицированная по классификации сердечной функции нью-йоркской кардиологической ассоциации (NYHA).
2. Применение по п.1, где хроническая сердечная недостаточность вызвана ишемическими, врожденными, ревматическими, идиопатическими, вирусными или токсическими факторами.
3. Применение по п.1, где нейрегулин используют вместе с по меньшей мере одним лекарственными средствами от сердечной недостаточности.
4. Применение по п.3, где по меньшей мере одно лекарственное средство от сердечной недостаточности выбрано из группы, состоящей из: ингибиторов ангиотензин-превращающего фермента (ACE), β-блокаторов, ARB, диуретиков и наперстянки.
5. Применение по п.1, где долгосрочное преимущество от лечения нейрегулином указывается c помощью уровня экспрессии биомаркера для диагностики или прогноза сердечной недостаточности.
6. Применение по п.5, где биомаркер представляет собой NT-proBNP или BNP.
7. Применение по п.1, где нейрегулин вводят пациентам во вводном режиме.
8. Применение по п.7, где вводный режим включает введение нейрегулина в течение, по крайней мере, 3, 5, 7 или 10 дней подряд.
9. Применение по п.7, где нейрегулин вводят пациентам для поддерживающего режима после вводного режима.
10. Применение по п.9, где поддерживающий режим включает введение нейрегулина каждые 3, 5, 7 или 10 дней.
11. Применение по п.1, где нейрегулин представляет собой нейрегулин-1.
12. Применение по п.1, где белок нейрегулина содержит EGF-подобный домен нейрегулина-1.
13. Применение по п.1, где нейрегулин содержит последовательность аминокислот SEQ ID NO: 1.
14. Способ лечения пациента с хронической сердечной недостаточностью, включающий стадию введения нейрегулина пациенту с хронической сердечной недостаточностью, чтобы таким образом лечить пациента, где у пациента есть сердечная функция класса II или класса III, классифицированная по классификации сердечной функции нью-йоркской кардиологической ассоциации (NYHA) до лечения нейрегулином.
15. Способ по п.14, где хроническая сердечная недостаточность вызвана ишемическими, врожденными, ревматическими, идиопатическими, вирусными или токсическими факторами.
16. Способ по п.14, где нейрегулин используют вместе с по меньшей мере одним лекарственными средствами от сердечной недостаточности.
17. Способ по п.16, где по меньшей мере одно лекарственное средство от сердечной недостаточности выбрано из группы, состоящей из: ингибиторов ангиотензин-превращающего фермента (ACE), β-блокаторов, ARB, диуретиков и наперстянки.
18. Способ по п.14, где долгосрочное преимущество от лечения нейрегулином указывается c помощью уровня экспрессии биомаркера для диагностики или прогноза сердечной недостаточности.
19. Способ по п.18, где биомаркер представляет собой NT-proBNP или BNP.
20. Способ по п.14, где нейрегулин вводят пациентам во вводном режиме.
21. Способ по п.20, где вводный режим включает введение нейрегулина в течение, по крайней мере, 3, 5, 7 или 10 дней подряд.
22. Способ по п.20, где нейрегулин вводят пациентам для поддерживающего режима после вводного режима.
23. Способ по п.22, где поддерживающий режим включает введение нейрегулина каждые 3, 5, 7 или 10 дней.
24. Способ по п.14, где нейрегулин представляет собой нейрегулин-1.
25. Способ по п.14, где белок нейрегулина содержит EGF-подобный домен нейрегулина-1.
26. Способ по п.14, где нейрегулин содержит последовательность аминокислот SEQ ID NO: 1.
27. Способ выбора пациента с сердечной недостаточностью для лечения нейрегулином, включающий проведение сопутствующего диагностического теста перед лечением, где диагностический тест сопутствующий диагностический тест представляет собой оценку сердечной функции по классификации сердечной функции NYHA, и решение того, является ли результат теста показательным для лечения пациента с помощью нейрегулина, где результат теста является показательным для лечения нейрегулином, когда сердечная функция относится к классу II или III по NYHA.
28. Способ по п.27, где нейрегулин представляет собой нейрегулин-1.
29. Способ по п. 27, где белок нейрегулина содержит EGF-подобный домен нейрегулина-1.
30. Способ по п. 27, где нейрегулин содержит последовательность аминокислот SEQ ID NO: 1.
RU2018103196A 2011-10-10 2012-10-08 Композиции и способы лечения сердечной недостаточности RU2018103196A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/CN2011/001691 WO2013053076A1 (en) 2011-10-10 2011-10-10 Compositions and methods for treating heart failure
CNPCT/CN2011/001691 2011-10-10
CNPCT/CN2011/081699 2011-11-02
PCT/CN2011/081699 WO2013053158A1 (en) 2011-10-10 2011-11-02 Compositions and methods for treating heart failure

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2014118584A Division RU2646481C2 (ru) 2011-10-10 2012-10-08 Композиции и способы лечения сердечной недостаточности

Publications (1)

Publication Number Publication Date
RU2018103196A true RU2018103196A (ru) 2019-02-22

Family

ID=48081325

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2018103196A RU2018103196A (ru) 2011-10-10 2012-10-08 Композиции и способы лечения сердечной недостаточности
RU2014118584A RU2646481C2 (ru) 2011-10-10 2012-10-08 Композиции и способы лечения сердечной недостаточности

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2014118584A RU2646481C2 (ru) 2011-10-10 2012-10-08 Композиции и способы лечения сердечной недостаточности

Country Status (11)

Country Link
US (3) US20140364366A1 (ru)
EP (3) EP3777879A1 (ru)
JP (5) JP6162128B2 (ru)
KR (5) KR102007757B1 (ru)
CN (2) CN109010801A (ru)
AU (4) AU2012323711B9 (ru)
BR (1) BR112014008446A2 (ru)
CA (1) CA2850560A1 (ru)
ES (2) ES2636753T3 (ru)
RU (2) RU2018103196A (ru)
WO (3) WO2013053076A1 (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2918283B1 (en) 2005-12-30 2018-01-31 Zensun (Shanghai) Science & Technology, Co., Ltd. Extended release of neuregulin for improved cardiac function
CN102470161A (zh) 2009-06-09 2012-05-23 上海泽生科技开发有限公司 神经调节蛋白用于治疗心力衰竭的有效剂量
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
EP2903632A4 (en) 2012-10-08 2016-07-13 Zensun Shanghai Science And Technology Ltd COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE IN DIABETES PATIENTS
CN112168953A (zh) 2013-05-22 2021-01-05 上海泽生科技开发股份有限公司 缓释纽兰格林治疗心力衰竭
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
CN105561298A (zh) * 2014-10-17 2016-05-11 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
CN113166218A (zh) 2018-04-11 2021-07-23 信立泰生物医药公司 人神经调节蛋白-1(nrg-1)重组融合蛋白组合物和其使用方法
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
CN111840517A (zh) * 2019-04-28 2020-10-30 上海泽生科技开发股份有限公司 神经调节蛋白用于长效预防、治疗或延迟心脏损伤的方法
RU2712634C1 (ru) * 2019-08-27 2020-01-30 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Способ прогнозирования сердечно-сосудистых осложнений у больных ишемической болезнью сердца в сочетании с ишемической митральной недостаточностью
CA3157354A1 (en) * 2019-09-16 2021-03-25 Zensun (Shanghai) Science & Technology, Co., Ltd. Recombinant human neuregulin derivatives and use thereof
CN112500493A (zh) * 2019-09-16 2021-03-16 上海泽生科技开发股份有限公司 重组人神经调节蛋白衍生物及其用途
CN113289002A (zh) * 2020-02-24 2021-08-24 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物
CN117797243A (zh) * 2022-09-30 2024-04-02 上海泽生科技开发股份有限公司 神经调节蛋白及其应用

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS607934A (ja) 1983-06-29 1985-01-16 Dai Ichi Seiyaku Co Ltd リポソ−ムの製造方法
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
ATE59966T1 (de) 1983-09-26 1991-02-15 Ehrenfeld Udo Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
US5272065A (en) 1983-10-20 1993-12-21 Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5906810A (en) 1987-03-17 1999-05-25 Turner; Robert E. Formulations and uses thereof in the prevention and treatment of oral lesions
WO1989001489A1 (en) 1987-08-10 1989-02-23 Commonwealth Scientific And Industrial Research Or Control of angiogenesis and compositions and methods therefor
SE463851B (sv) 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH02226533A (ja) 1989-02-27 1990-09-10 Mitsubishi Electric Corp 情報記録媒体
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5580722A (en) 1989-07-18 1996-12-03 Oncogene Science, Inc. Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease
EP0950707B1 (en) 1989-07-25 2009-02-18 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
GB9107566D0 (en) 1991-04-10 1991-05-29 Ludwig Inst Cancer Res Glial mitogenic factors,their preparation and use
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5367060A (en) 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US6087323A (en) 1992-04-03 2000-07-11 Cambridge Neuroscience, Inc. Use of neuregulins as modulators of cellular communication
US7037888B1 (en) 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
DE4221256C2 (de) 1992-06-26 1997-07-10 Lancaster Group Ag Galenische Zusammensetzung für die topische Anwendung
NO942396L (no) 1993-06-24 1994-12-27 Takeda Chemical Industries Ltd Preparat med vedvarende frigiving av anti-endotelin substans
US5770567A (en) 1994-11-14 1998-06-23 Genentech, Inc. Sensory and motor neuron derived factor (SMDF)
EP0815224B1 (en) 1995-03-10 2004-07-21 Genentech, Inc. Receptor activation by gas6
US6750196B1 (en) 1995-03-27 2004-06-15 Acorda Therapeutics Methods of treating disorders of the eye
US5741511A (en) 1995-04-12 1998-04-21 Sam Yang Co., Ltd. Transdermal drug delivery device for treating erectile dysfunction
US5714385A (en) 1995-05-10 1998-02-03 Genentech, Inc. Media for culturing schwann cells
US5721139A (en) 1995-05-10 1998-02-24 Genentech, Inc. Isolating and culturing schwann cells
US6033660A (en) 1995-05-10 2000-03-07 Genentech, Inc. Method of treating a nervous system injury with cultured schwann cells
US5624902A (en) 1995-06-07 1997-04-29 Torrey Pines Institute For Molecular Studies Peptide inhibitors of calmodulin
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
US5941868A (en) 1995-12-22 1999-08-24 Localmed, Inc. Localized intravascular delivery of growth factors for promotion of angiogenesis
US5736154A (en) 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
CA2246429C (en) 1996-03-27 2007-07-24 Genentech, Inc. Erbb3 antibodies
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
AU727606B2 (en) 1996-07-12 2000-12-14 Genentech Inc. Gamma-heregulin
US6593290B1 (en) 1996-11-01 2003-07-15 Genentech, Inc. Treatment of inner ear hair cells
US6156728A (en) 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
US6387638B1 (en) 1997-02-10 2002-05-14 Genentech, Inc. Heregulin variants
US6136558A (en) 1997-02-10 2000-10-24 Genentech, Inc. Heregulin variants
US5955594A (en) 1997-04-30 1999-09-21 Mishra; Lopa Nucleic acids encoding proteins for early liver development
WO1998055611A1 (en) 1997-06-06 1998-12-10 Regents Of The University Of Michigan Neuregulin response element and uses therefor
US6121415A (en) 1997-07-09 2000-09-19 Genentech, Inc. ErbB4 receptor-specific neuregolin related ligands and uses therefor
SE9703226D0 (sv) 1997-09-08 1997-09-08 Astra Ab New pharmaceutical composition
AU745324B2 (en) 1997-10-14 2002-03-21 Cenes Pharmaceuticals, Inc. Therapeutic methods comprising use of a neuregulin
US6197801B1 (en) 1998-01-14 2001-03-06 Usa Doctors Products, Inc. Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction
WO1999049062A1 (en) 1998-03-26 1999-09-30 Gene Logic, Inc. IDENTIFICATION OF A cDNA ASSOCIATED WITH ISCHEMIA IN HUMAN HEART TISSUE
US6054261A (en) 1998-05-20 2000-04-25 Q-Pharma, Inc. Coenzyme Q10 compositions for organ protection during perfusion
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
JP2004513607A (ja) 2000-02-28 2004-05-13 デコード　ジェネティクス　イーエッチエフ． ヒト精神分裂病遺伝子
US20010041869A1 (en) 2000-03-23 2001-11-15 Causey James D. Control tabs for infusion devices and methods of using the same
AU7494701A (en) 2000-05-23 2001-12-03 Cenes Pharmaceuticals Inc Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
US6589229B1 (en) 2000-07-31 2003-07-08 Becton, Dickinson And Company Wearable, self-contained drug infusion device
AU2001290864A1 (en) 2000-09-12 2002-04-02 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Optimized cardiac contraction through differential phosphorylation of myosin
US6482624B2 (en) 2000-11-14 2002-11-19 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2002048191A2 (en) 2000-12-11 2002-06-20 Yeda Research And Development Co. Ltd. Inhibitory agents derived from specific growth factors
RU2180843C1 (ru) 2001-02-19 2002-03-27 Новокузнецкий государственный институт усовершенствования врачей Способ профилактики повторного инфаркта миокарда
CA2448320A1 (en) 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Ribozyme based treatment of female reproductive diseases
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
JP2005510501A (ja) 2001-10-19 2005-04-21 マキシム ファーマシューティカルス，インコーポレイテッド 肝臓疾患治療へのヒスタミンの使用
EP1495123B1 (en) 2002-03-26 2013-10-30 Zensun (Shanghai) Science and Technology Limited Erbb3 based methods and compositions for treating neoplasms
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
AU2003240688A1 (en) 2002-05-24 2003-12-12 Bayer Aktiengesellschaft Regulation of human kinase
CN1498656A (zh) 2002-11-08 2004-05-26 上海泽生科技开发有限公司 神经调节蛋白用于心肌梗死治疗的方法和组合物
US7144384B2 (en) 2002-09-30 2006-12-05 Insulet Corporation Dispenser components and methods for patient infusion device
US7128727B2 (en) 2002-09-30 2006-10-31 Flaherty J Christopher Components and methods for patient infusion device
EP1573045A4 (en) 2002-11-27 2007-02-21 Artesian Therapeutics Inc DETECTION OF GENES RELATED TO HEART FAILURE AND THERAPEUTIC ASSAY
AU2004249114A1 (en) 2003-05-21 2004-12-29 Board Of Regents, The University Of Texas System Inhibition of protein kinase C-mu (PKD) as a treatment for cardiac hypertrophy and heart failure
JP4792582B2 (ja) 2003-08-21 2011-10-12 国立大学法人大阪大学 心肥大及びそれに起因する心疾患を予防または治療するための医薬組成物
US7341835B2 (en) 2004-01-13 2008-03-11 Affymetrix, Inc. Methods of analysis of alternative splicing in mouse
US20080039434A1 (en) 2004-03-01 2008-02-14 Bioxell S. P.A. Treatment of Interstitial Cystitis with Vitamin D Compounds
CN1715926B (zh) 2004-07-02 2011-08-17 上海泽生科技开发有限公司 神经调节蛋白突变体的应用
CN1743006A (zh) 2004-09-02 2006-03-08 上海泽生科技开发有限公司 Mapk抑制剂的新用途及组合物
CN1743005A (zh) 2004-09-02 2006-03-08 上海泽生科技开发有限公司 Pi3－k抑制剂的新用途及组合物
US20060160062A1 (en) 2005-01-14 2006-07-20 Young Lindon H Perfusion and/or preservation solution for organs
US20070141548A1 (en) 2005-03-11 2007-06-21 Jorg Kohl Organ transplant solutions and method for transplanting organs
US9233203B2 (en) 2005-05-06 2016-01-12 Medtronic Minimed, Inc. Medical needles for damping motion
EP1731910A1 (en) * 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
CN100361709C (zh) 2005-08-30 2008-01-16 山东省生物药物研究院 一种对生命活性物质有保护作用的糖类组合
CN1768859A (zh) 2005-10-24 2006-05-10 天津大学 基于醛基的微粒表面多重生物功能因子组装方法
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
CN101394861A (zh) * 2005-12-30 2009-03-25 上海泽生科技开发有限公司 纽兰格林持续给药能改善心脏功能
EP2918283B1 (en) 2005-12-30 2018-01-31 Zensun (Shanghai) Science & Technology, Co., Ltd. Extended release of neuregulin for improved cardiac function
US9580515B2 (en) 2006-08-21 2017-02-28 Zensun (Shanghai) Science & Technology, Co., Ltd. Neukinase, a downstream protein of neuregulin
EP2115477B1 (en) * 2007-01-25 2015-06-24 Roche Diagnostics GmbH Use of igfbp-7 in the assessment of heart failure
US20100129815A1 (en) 2007-04-13 2010-05-27 Univeristy Of Florida Research Foundation Inc. Identification of cardiac specific myosin light chain kinase
CN101310766B (zh) 2007-05-25 2014-04-16 上海泽生科技开发有限公司 神经调节蛋白的新用途
CN101310779A (zh) 2007-05-25 2008-11-26 上海泽生科技开发有限公司 包含神经调节蛋白的装置及药物制剂
US20090156488A1 (en) * 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
PL3338791T3 (pl) 2008-07-17 2020-04-30 Acorda Therapeutics, Inc. Terapeutyczne dawkowanie neureguliny do leczenia lub zapobiegania niewydolności serca
EP2370458B1 (en) 2008-11-28 2014-10-15 Zensun (Shanghai) Science and Technology Limited Neuregulin peptides and their use
JP2012509908A (ja) 2008-11-28 2012-04-26 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド ニューレグリン及び心臓幹細胞
BRPI0920976A2 (pt) 2008-12-03 2015-08-18 Amorcyte Inc Composições que melhoram a perfusão da area de infarto e metodos de restauração da lesão vascular.
CN102470161A (zh) 2009-06-09 2012-05-23 上海泽生科技开发有限公司 神经调节蛋白用于治疗心力衰竭的有效剂量
WO2010142141A1 (en) * 2009-06-09 2010-12-16 Zensun (Shanghai) Science & Technology Limited Neuregulin based methods for treating heart failure
US20120121557A1 (en) 2009-07-22 2012-05-17 Children's Medical Center Corporation Neuregulin induced proliferation of cardiomyocytes
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
SI2544537T1 (sl) 2010-03-10 2017-12-29 Cempra Pharmaceuticals, Inc. Formulacije makrolidnih antibiotikov za parenteralni vnos
KR101800040B1 (ko) 2010-03-10 2017-11-21 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 릴랙신을 사용한 아쿠아포린의 조절
US9029328B2 (en) 2010-03-24 2015-05-12 The Brigham And Women's Hospital, Inc. Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands
CN104997803B (zh) 2010-07-22 2019-07-09 雷文制药有限公司 包含使用磁偶极子稳定化溶液的治疗或改善疾病并增强表现的方法和组合物
FR2972328A1 (fr) 2011-03-07 2012-09-14 Walmark A S Complement alimentaire augmentant la protection de l'epithelium des voies urinaires basses contre les infections a repetition
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
CN103127579B (zh) 2011-11-21 2017-06-16 上海泽生科技开发股份有限公司 便携式注射泵的驱动系统
US20130143845A1 (en) 2011-12-05 2013-06-06 William Francis Supple Vitamin d compounds and methods for enhancing muscle strength, and prevention and treatment of disease in human beings
EP2833923A4 (en) 2012-04-02 2016-02-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
EP2903632A4 (en) 2012-10-08 2016-07-13 Zensun Shanghai Science And Technology Ltd COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE IN DIABETES PATIENTS
AU2014225534A1 (en) 2013-03-06 2015-09-24 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
CN112168953A (zh) 2013-05-22 2021-01-05 上海泽生科技开发股份有限公司 缓释纽兰格林治疗心力衰竭
CN104337813A (zh) 2013-07-23 2015-02-11 上海泽生科技开发有限公司 使用维生素b组合物促进胃肠系统动力的方法
CN104758300A (zh) 2014-01-02 2015-07-08 上海泽生科技开发有限公司 维生素d及其组合物的抗菌用途
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
CN105561298A (zh) 2014-10-17 2016-05-11 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
CN106177992A (zh) 2015-05-08 2016-12-07 上海泽生科技开发有限公司 cMLCK基因导入

Also Published As

Publication number Publication date
EP2766390B1 (en) 2017-06-14
WO2013053158A1 (en) 2013-04-18
KR20140076570A (ko) 2014-06-20
US20140364366A1 (en) 2014-12-11
AU2022203800A1 (en) 2022-06-23
KR20220035263A (ko) 2022-03-21
AU2017251758A1 (en) 2017-11-16
AU2019284050A1 (en) 2020-01-23
CA2850560A1 (en) 2013-04-18
AU2012323711B9 (en) 2017-08-10
CN103857695A (zh) 2014-06-11
US20170326204A1 (en) 2017-11-16
KR20190093690A (ko) 2019-08-09
US20220362339A1 (en) 2022-11-17
WO2013053076A1 (en) 2013-04-18
JP6162128B2 (ja) 2017-07-12
JP2017206527A (ja) 2017-11-24
WO2013053201A1 (en) 2013-04-18
JP2023036871A (ja) 2023-03-14
AU2012323711A1 (en) 2014-04-17
KR102007757B1 (ko) 2019-08-06
EP2766390A1 (en) 2014-08-20
AU2012323711B2 (en) 2017-07-27
JP2021098729A (ja) 2021-07-01
US11253573B2 (en) 2022-02-22
EP3777879A1 (en) 2021-02-17
EP3135685B1 (en) 2020-07-29
EP2766390A4 (en) 2015-03-18
KR20200142109A (ko) 2020-12-21
EP3135685A1 (en) 2017-03-01
AU2017251758B2 (en) 2019-09-26
RU2014118584A (ru) 2015-11-20
JP7209382B2 (ja) 2023-01-20
AU2019284050B2 (en) 2022-03-17
KR20230119049A (ko) 2023-08-14
RU2646481C2 (ru) 2018-03-05
JP2019142906A (ja) 2019-08-29
JP2015501297A (ja) 2015-01-15
ES2812104T3 (es) 2021-03-16
BR112014008446A2 (pt) 2020-09-15
ES2636753T3 (es) 2017-10-09
CN109010801A (zh) 2018-12-18

Similar Documents

Publication Publication Date Title
RU2018103196A (ru) Композиции и способы лечения сердечной недостаточности
JP2015501297A5 (ja) 医薬組成物、方法、診断キット
Nalbandian et al. Post-acute COVID-19 syndrome
Deng et al. Suspected myocardial injury in patients with COVID-19: evidence from front-line clinical observation in Wuhan, China
Drazner The progression of hypertensive heart disease
Morello et al. Association of atrial fibrillation and amino-terminal pro–brain natriuretic peptide concentrations in dyspneic subjects with and without acute heart failure: Results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study
Kawaji et al. Clinical impact of left ventricular outflow tract obstruction in takotsubo cardiomyopathy
Riccardi et al. Heart failure: an update from the last years and a look at the near future
JP6266146B2 (ja) ニューレグリンに基づく心不全の治療方法
Tang et al. Is CHA2DS2-VASc score a predictor of left atrial thrombus in patients with paroxysmal atrial fibrillation?
Kiuchi et al. New approaches in the management of sudden cardiac death in patients with heart failure—targeting the sympathetic nervous system
Song et al. The impact of stressor patterns on clinical features in patients with tako‐tsubo cardiomyopathy: experiences of two tertiary cardiovascular centers
JP2013503110A (ja) ニューレグリンに基づく心不全の治療方法
Abi Nassif et al. Cardiac manifestations in COVID‐19 patients: A focus on the pediatric population
Pellicori et al. Heart failure with preserved ejection fraction
Nadkarni et al. Diastolic dysfunction, prolonged QTc interval and pericardial effusion as predictors of mortality in acute pancreatitis
Cirillo et al. Increased high mobility group box-1 protein levels are associated with impaired cardiopulmonary and echocardiographic findings after acute myocardial infarction
Kępińska et al. Advanced heart failure: A review
Agostoni et al. Heart failure patients with improved ejection fraction: Insights from the MECKI score database
Naito et al. Prevalence of transthyretin amyloidosis among heart failure patients with preserved ejection fraction in Japan
ES2603197T3 (es) Péptido natriurético pro-auricular en la región media (MR-proANP) para la identificación de pacientes con fibrilación auricular con un inicio de menos de 48 horas
Potpara et al. Lone atrial fibrillation: where are we now?
Petutschnigg et al. Heart failure with mid-range ejection fraction and with preserved ejection fraction
Ślusarczyk et al. Outcomes of COVID-19 in hospitalized kidney and liver transplant recipients: a single-center experience
Ritzel et al. Impact of lifestyle modifi cation on left ventricular function and cardiopulmonary exercise capacity in patients with heart failure with normal ejection fraction and cardiometabolic syndrome: a prospective interventional study

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20151009